tiprankstipranks
Blurbs

Foghorn Therapeutics (FHTX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Foghorn Therapeutics (FHTXResearch Report), with a price target of $25.00. The company’s shares closed last Monday at $10.05, close to its 52-week low of $8.01.

According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -23.4% and a 19.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

Foghorn Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $24.34 and a one-year low of $8.01. Currently, Foghorn Therapeutics has an average volume of 141.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Read More on FHTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More